4 ms·
This looked like one of the most promising therapeutics early on, was wondering what happened to it. Here's a great breakdown of how it works by the founder of
by dharma1 6y ago
This looked like one of the most promising therapeutics early on, was wondering what happened to it.
Here's a great breakdown of how it works by the founder of Apeiron, Dr Joseph Penninger, from March. https://www.youtube.com/watch?v=jAW6VBWTiAA https://www.youtube.com/watch?v=jAW6VBWTiAA
It has been since discovered that there are other receptors/pathways too for SARS-CoV-2 to enter the cell, but it's still unclear which ones are the main culprits.
https://theconversation.com/a-second-pathway-into-cells-for-sars-cov-2-new-understanding-of-the-neuropilin-1-protein-could-speed-vaccine-research-148497 https://theconversation.com/a-second-pathway-into-cells-for-...
- sradman 6y agoI too tried to follow the progress of Apeiron's APN01 which started to get news coverage at the end of February due to a University of British Columbia press release [1]. This pre-existing therapeutic was created out of SARS-CoV-1 research and I expected a SARS-CoV-2 trial to be accelerated. It never happened. There is a story to be told here. Either a missed opportunity, incompetence, or a complete misunderstanding on my part of what a promising COVID-19 therapeutic looks like. [1] https://www.med.ubc.ca/news/pilot-clinical-trial-in-china-to-test-ubc-researchers-findings-as-a-targeted-therapy-for-covid-19/ https://www.med.ubc.ca/news/pilot-clinical-trial-in-china-to...
- deleted 6y ago[deleted]